Preparation and characterization of fenofibrate-loaded zeolitic imidazolate frameworks and their evaluation in dissolution enhancement of the formulation

Document Type : Original Article

Authors

1 Zanjan Pharmaceutical Nanotechnology Research Center (ZPNRC), Zanjan University of Medical Sciences.

2 Department of Pharmaceutics, School of pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

3 Department of Pharmaceutical Nanotechnology, School of pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.

4 Department of Pharmaceutical Nanotechnology, School of pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran & Trita Nanomedicine Research Center (TNRC), Trita Third Millennium Pharmaceuticals, Zanjan, Iran

5 4Trita Nanomedicine Research Center (TNRC), Trita Third Millennium Pharmaceuticals, Zanjan, Iran.

6 Department of Pharmaceutical Nanotechnology, School of pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran & Zanjan Pharmaceutical Nanotechnology Research Center (ZPNRC), Zanjan University of Medical Sciences,

Abstract

The purpose of this study was to develop zeolitic imidazolate frameworks (ZIFs) incorporated with poorly water-soluble drug fenofibrate (FEN), belonging to Biopharmaceutical Classification System (BCS) class II, to improve drug dissolution, intended to be orally administrated. FEN-loaded ZIF-8 were characterized with N2 adsorption-desorption analysis, fourier transform infrared spectroscopy (FT-IR), powder X-ray diffraction (PXRD), and dynamic light scattering (DLS) with the results demonstrating the successful incorporation of FEN into the ZIF-based host. Different parameters including similarity factor (f2), difference factor (f1), dissolution efficiency (DE%) and mean dissolution time (MDT) were employed to analyze drug release tests, confirming a significant enhancement in the release profile of FEN with ZIF-8 as drug dissolution enhancer. Compared to enzyme-free simulated intestinal fluid (SIF), remarkable dissolution enhancement of FEN was observed in enzyme-free simulated gastric fluid (SGF) as drug release media. Fitting the experimental data from the release studies to different kinetic models showed the best fitting with Weibull, First order with Fmax and Korsmeyer-Peppas models.

Keywords


[1] Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, S. Onoue, International Journal of Pharmaceutics. 420 (2011) 1.
[2] A. Maleki, H. Kettiger, A. Schoubben, J.M. Rosenholm, V. Ambrogi, M. Hamidi, Journal of Controlled Release. 262 (2017) 329.
[3] Y. Chen, Y. Lu, J. Chen, J. Lai, J. Sun, F. Hu, W. Wu, International Journal of Pharmaceutics. 376 (2009) 153.
[4] L. Hu, H. Wu, F. Niu, C. Yan, X. Yang, Y. Jia, International Journal of Pharmaceutics. 420 (2011) 251.
[5] P. Horcajada, T. Chalati, C. Serre, B. Gillet, C. Sebrie, T. Baati, J.F. Eubank, D. Heurtaux, P. Clayette, C. Kreuz, Nature Materials. 9 (2010) 172.
[6] X. Unamuno, E. Imbuluzqueta, F. Salles, P. Horcajada, M. Blanco-Prieto, European Journal of Pharmaceutics and Biopharmaceutics. 132 (2018) 11.
[7] S. Rojas, T. Baati, L. Njim, L. Manchego, F. Neffati, N. Abdeljelil, S. Saguem, C. Serre, M.F. Najjar, A. Zakhama, Journal of the American Chemical Society. 140 (2018) 9581.
[8] J. Zhuang, C.-H. Kuo, L.-Y. Chou, D.-Y. Liu, E. Weerapana, C.-K. Tsung, ACS Nano. 8 (2014) 2812.
[9] C.A. McCarthy, W. Faisal, J.P. O’Shea, C. Murphy, R.J. Ahern, K.B. Ryan, B.T. Griffin, A.M. Crean, Journal of Controlled Release. 250 (2017) 86.
[10] Y. Zhang, M. Huo, J. Zhou, A. Zou, W. Li, C. Yao, S. Xie, The AAPS Journal. 12 (2010) 263.
[11] Y. Fei, E.S. Kostewicz, M.-T. Sheu, J.B. Dressman, European Journal of Pharmaceutics and Biopharmaceutics. 85 (2013) 1274.
[12] P. Costa, J.M.S. Lobo, European Journal of Pharmaceutical Sciences. 13 (2001) 123.
[13] Y. Hu, H. Kazemian, S. Rohani, Y. Huang, Y. Song, Chemical Communications. 47 (2011) 12694.
[14] K.E.A. AbouAitah, A.A. Farghali, A. Swiderska-Sroda, W. Lojkowski, A.M. Razin, M.K. Khedr, J Nanomed Nanotechnol. 7 (2016).